Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial



Guo, Yutao, Lane, Deirdre A ORCID: 0000-0002-5604-9378, Wang, Liming, Chen, Yundai, Lip, Gregory YH ORCID: 0000-0002-7566-1626, Wang, Liming, Eckstein, Jens, Thomas, G Neil, Feng, Mei, Liu, Xuejun
et al (show 62 more authors) (2019) Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 73 (7). e13352-.

[img] Text
MAFA II project_ACCEPTED.pdf - Author Accepted Manuscript

Download (602kB)
[img] Text
MAFA II Figures_ACCEPTED.pdf - Author Accepted Manuscript

Download (749kB)

Abstract

<h4>Background</h4>Current management of patients with atrial fibrillation (AF) is limited by low detection of AF, non-adherence to guidelines and lack of consideration of patient's preferences, thus highlighting the need for a holistic and integrated approach to AF management. This study aims to determine whether a mHealth technology-supported AF integrated management strategy will reduce AF-related adverse events.<h4>Methods/design</h4>The mAFA II trial is a prospective, cluster randomised controlled trial. The 40 sites will be randomised to mAFA-integrated care intervention or usual care arms. Prior to randomisation, study sites will be paired to be matched in size and the proportion of study eligible patients. All AF patients aged over 18 years old with CHA<sub>2</sub> DS<sub>2</sub> -VASc score ≥ 2 will be enrolled. Assuming a composite adverse event rate of 10% pre-intervention, reduced to 5% after intervention, we aim to recruit 3660 patients assuming a 10% loss to follow-up. The primary study endpoint is a composite of stroke/thromboembolism, all-cause death and rehospitalisation. Ancillary analyses would determine patient-related outcome measures, health economics and cost effectiveness, as well as an embedded qualitative study.<h4>Discussion</h4>The mAFA II trial will provide evidence for an integrated care approach to holistic AF care, supported by mobile health technology to improve screening, patient involvement and optimisation of management.

Item Type: Article
Uncontrolled Keywords: mAF-App II Trial investigators, Humans, Atrial Fibrillation, Prospective Studies, Telemedicine, Research Design, Adolescent, Adult, Aged, Middle Aged, Patient Participation, Cost-Benefit Analysis, Delivery of Health Care, Integrated, China, Female, Male, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Outcome Assessment, Health Care
Depositing User: Symplectic Admin
Date Deposited: 23 Apr 2019 10:11
Last Modified: 02 Apr 2024 09:26
DOI: 10.1111/ijcp.13352
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3038028